Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMY-922 in Refractory Hematologic Malignancies
NCT07679919Phase 1Not yet recruiting
- Sponsor
- Luminary Therapeutics
- Start
- Sep 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of LMY-922 in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL) and 1 more (12 arms), sponsored by Luminary Therapeutics. Primary endpoints: Safety profile of LMY-922 at 12 Months and Recommended Phase II Dose at 12 Months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
LMY-922
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)hairy cell leukemia (HCL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07679919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07679919.